AstraZeneca plc 43.3% Potential Upside Indicated by Citigroup

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc with EPIC/TICKER (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Citigroup. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Citigroup have set a target price of 10000 GBX on its stock. This is indicating the analyst believes there is a potential upside of 43.3% from the opening price of 6977 GBX. Over the last 30 and 90 trading days the company share price has decreased 353 points and increased 784 points respectively. The 52 week high share price is 7583 GBX while the 52 week low for the share price is 5312 GBX.

AstraZeneca plc has a 50 day moving average of 7,043.84 GBX and the 200 Day Moving Average price is recorded at 6,308.83. There are currently 1,311,882,856 shares in issue with the average daily volume traded being 2,165,131. Market capitalisation for LON:AZN is £90,428,085,264 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.

      Search

      Search